| Literature DB >> 23695671 |
Ching-Wen Lin1, Yih-Leong Chang, Yu-Chiuan Chang, Jau-Chen Lin, Chun-Chi Chen, Szu-Hua Pan, Chen-Tu Wu, Hsuan-Yu Chen, Shuenn-Chen Yang, Tse-Ming Hong, Pan-Chyr Yang.
Abstract
Dysregulation of microRNAs has a critical role in cancer progression. Here we identify an intronic microRNA, miR-135b that is upregulated in highly invasive non-small-cell lung cancer cells. Expression of miR-135b enhances cancer cell invasive and migratory abilities in vitro and promotes cancer metastasis in vivo, while specific inhibition of miR-135b by a miR-135b-specific molecular sponge and antagomirs suppresses cancer cell invasion, orthotopic lung tumour growth and metastasis in a mouse model. miR-135b targets multiple key components in the Hippo pathway, including LATS2, β-TrCP and NDR2, as well as LZTS1. Expression of miR-135b, LZTS1, LATS2 and nuclear TAZ predicts poor outcomes of non-small-cell lung cancer. We find that miR-135b is dually regulated by DNA demethylation and nuclear factor-kappaB signalling, implying that abnormal expression of miR-135b in cancer may result from inflammatory and epigenetic modulations. We conclude that miR-135b is an oncogenic microRNA and a potential therapeutic target for non-small-cell lung cancer.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23695671 DOI: 10.1038/ncomms2876
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919